Gouty Arthritis Market Analysis Report, Regional Outlook with Key Players – Takeda Pharmaceutical Company, Savient Pharmaceuticals, GlaxoSmithKline, Teijin Pharma, Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, Nippon Chemiphar

Coherent Market Insights has announced the addition of the “Gouty Arthritis Market Size Status and Forecast 2026”, The report classifies the global Gouty Arthritis Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Gouty Arthritis Speaker market, analyzes and researches the Gouty Arthritis Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Takeda Pharmaceutical Company, Savient Pharmaceuticals, GlaxoSmithKline, Teijin Pharma, Regeneron Pharmaceuticals, JW Pharmaceutical Corporation, Nippon Chemiphar

Request a sample copy of gouty arthritis market : https://www.coherentmarketinsights.com/insight/request-sample/1368

Gouty arthritis is characterized by intense joint pain due to deposition of uric acid crystals. Symptoms of gouty arthritis include redness and swelling of joints and intense pain. The condition can be treated with the help of medication. Uric acid is deposited either due to its excess intake or body’s inability to process it leading to inflammation of joint sites such as ankles and toes or wrist. Untreated gouty arthritis may damage joints or kidney as excessive accumulation of uric acid crystals would lead to kidney stone, kidney failure. In most cases, it is observed with other metabolic diseases or conditions such as hypertension, obesity, and diabetes.

High prevalence of associated chronic diseases to provide growth to gouty arthritis market

Other comorbidities such as hypertension is often associated with gout. As per study published in Journal of Rheumatology in 2014, around 75% of gouty arthritis patient were reported to be suffering from hypertension. Therefore patients suffering from chronic disease are at high risk of developing gouty arthritis .High prevalence of gouty arthritis is expected to drive the growth for global gouty arthritis market. According to study published in British Medical Journal in 2017, prevalence of gouty arthritis is 1% to 10% globally. Furthermore, factors such as increasing consumption of high protein food worldwide, linked with gouty arthritis and increasing awareness amongst people for early treatment of disease are the factors boosting growth of gouty arthritis market.

On the basis of Drug Class

NSAIDs
Corticosteroids
Colchicine
Urate-lowering agents

On the basis of gouty types

Acute gouty arthritis
Chronic gouty arthritis

North America is expected to dominate gouty arthritis market, owing high prevalence of gouty arthritis in the U.S. According to Centre for Disease Control and Prevention (CDC), an estimated 54.4 million patients annually suffered from some form of arthritis from 2013 - 2015, in which gouty arthritis carries significant share. According to clinical guidelines for gout published in Annals of Internal Medicine in 2017, about 3.9% of U.S. adults older than 20 years reported about gout at least once in lifetime. Furthermore, increasing geriatric population is driving growth of the market, owing to high prevalence of gouty arthritis in patients above 40 years of age. New and effective therapies to treat gouty arthritis are expected to fuel growth of gouty arthritis market.

-In August 2017, FDA approved first fixed dose combination called Duzallo (Ironwood Pharmaceuticals) of lesinurad with allopurinol to treat hyperuricemia in patients with uncontrolled gout. Duzallo is a one a day combination oral treatment.

-In 2015, Prasco Laboratories and Takeda Pharmaceutical Inc. entered into a distribution and supply agreement for the rights to distribute Colchicine Tablets, USP, which is generic version of Colrycs, colchicine brand by Takeda Pharmaceutical Inc., this would strengthen the distribution for colchicine and improve accessibility.

-Novartis in 2013 received European commission approval for Ilaris in treatment of acute gouty arthritis for patients who suffer from frequent attacks of gouty arthritis and are contraindicated to use other treatment option. Illaris is first biologic product to be used in gouty arthritis in Europe.

Else place an Inquire before Purchase “Gouty Arthritis Market Size, Status and Forecast 2026 : https://www.coherentmarketinsights.com/insight/talk-to-analyst/1368

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.